Publicaciones en colaboración con investigadores/as de University of North Carolina at Chapel Hill (16)

2022

  1. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

    Cell, Vol. 179, Núm. 5, pp. 1191-1206.e21

  3. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

    European Journal of Cancer, Vol. 117, pp. 91-98

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2016

  1. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89

2015

  1. Defining breast cancer intrinsic subtypes by quantitative receptor expression

    Oncologist, Vol. 20, Núm. 5, pp. 474-482

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

  2. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2013

  1. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

    Breast Cancer Research and Treatment, Vol. 138, Núm. 2, pp. 457-466

  2. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 203-209

  3. Reply to Y. Yamamoto et al

    Journal of Clinical Oncology

2012

  1. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

    BMC Medical Genomics, Vol. 5

2011

  1. Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in Situ hybridization

    American Journal of Pathology, Vol. 178, Núm. 4, pp. 1453-1460

2009

  1. Reply to L.C. Panasci

    Journal of Clinical Oncology

  2. Reply to R.S. Mehta et al

    Journal of Clinical Oncology